Sibaja JJD

Idioma: Español
Referencias bibliográficas: 16
Paginas: 503-506
Archivo PDF: 166.68 Kb.

RESUMEN

El asma es una enfermedad crónica, compleja y multifactorial de las vías aéreas que resulta en una hiperrespuesta de la vía aérea y que se manifiesta con silbidos, tos, disnea, entre otros. En un porcentaje de los pacientes asmáticos estos pacientes permanecen sin control a pesar del uso de altas dosis de esteroides inhalados en combinación con otros medicamentos. En estos casos de asma severa/refractaria nuevas terapias y estrategias han surgido como opción para el manejo de estos pacientes.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Aaron SD, Vandemheen KL, Boulet LP, McIvor RA, Fitzgerald JM, Hernandez P. et al. Overdiagnosis of asthma in obese and nonobese adults. Can Med Assoc J. 2008; 179(11):1121–31.

2. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory Effects of Macrolide Antibiotics—Part 2: Advantages and Disadvantages of Long Term, Low-Dose Macrolide Therapy. Respiration. 2011; 81(1):75–87.

3. Azuma A, Kudoh S. Diffuse panbronchiolitis in East Asia. Respirology. 2006; 11(3):249–61.

4. Denning DW, O’Driscoll BR, Powell G, Chew F, Atherton GT, Vyas A, et al. Randomized Controlled Trial of Oral Antifungal Treatment for Severe Asthma with Fungal Sensitization: The Fungal Asthma Sensitization Trial (FAST) Study. Am J Respir Crit Care Med. 2009; 179(1):11–8.

5. Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, et al. Effects of Treatment with Anti-immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic Asthma. Am J Respir Crit Care Med. 2004; 170(6):583–93.

6. Ernst P, Fitzgerald JM, Spier S. Canadian Asthma Consensus Conference Summary of recommendations. Can Respir J. 1996; 3(2):89–114.

7. Haselden BM, Kay AB, Larche M. Peptide-mediated immune responses in specific immunotherapy. Int Arch Allergy Immunol. 2000; 122(4):229–37.

8. Kostadima E, Tsiodras S, Alexopoulos EI, Kaditis AG, Mavrou I, Georgatou N, et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. European Respiratory Journal. 2004; 23(5):714–7.

9. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med. 2010; 181(4):315–23.

10. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program: Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma (Full Report 2007). http://www nhlbi nih.gov/ guidelines/asthma/asthgdln.pdf NIH publication no.08-4051. 2011. Bethesda, MD.

11. Pavord ID, Cox G, Thomson NC, Rubin AS, Corris PA, Niven RM, et al. Safety and Efficacy of Bronchial Thermoplasty in Symptomatic, Severe Asthma. Am J Respir Crit Care Med. 2007; 176(12):1185–91.

12. Proceedings of the ATS Workshop on Refractory Asthma. Current Understanding, Recommendations, and Unanswered Questions. Am J Respir Crit Care Med. 2000; 162(6):2341–51.

13. Soler M, Matz J, Townley R, Buhl R, O’Brien J, Fox H, et al. The anti- IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. European Respiratory Journal. 2001; 18(2):254– 61.

14. Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, usse W, Dhlen SE, et al. A Randomized, Double-blind, Placebocontrolled Study of Tumor Necrosis Factor-α Blockade in Severe Persistent Asthma. Am J Respir Crit Care Med. 2009; 179(7):549–58.

15. Wenzel SE, Busse WW. Severe asthma: Lessons from the Severe Asthma Research Program. J Allergy Clin Immunol. 2007; 119(1):14–21.

16. Zureik M, Neukirch C, Leynaert B+, Liard R, Bousquet J, Neukirch F. Sensitisation to airborne moulds and severity of asthma: cross sectional study from European Community respiratory health survey. BMJ. 2002; 325(7361):411.